These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15956985)

  • 1. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.
    Weerts EM; Kim YK; Wand GS; Dannals RF; Lee JS; Frost JJ; McCaul ME
    Neuropsychopharmacology; 2008 Feb; 33(3):653-65. PubMed ID: 17487229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
    Liao RF; Zeng ZP; Wen YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.
    Greenwald M; Johanson CE; Bueller J; Chang Y; Moody DE; Kilbourn M; Koeppe R; Zubieta JK
    Biol Psychiatry; 2007 Jan; 61(1):101-10. PubMed ID: 16950210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
    Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
    Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.
    Heinz A; Reimold M; Wrase J; Hermann D; Croissant B; Mundle G; Dohmen BM; Braus DF; Schumann G; Machulla HJ; Bares R; Mann K
    Arch Gen Psychiatry; 2005 Jan; 62(1):57-64. PubMed ID: 15630073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx).
    Cole A; Mutlow A; Isaza R; Carpenter JW; Koch DE; Hunter RP; Dresser BL
    J Zoo Wildl Med; 2006 Sep; 37(3):318-26. PubMed ID: 17319131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus).
    Mutlow A; Isaza R; Carpenter JW; Koch DE; Hunter RP
    J Zoo Wildl Med; 2004 Dec; 35(4):489-96. PubMed ID: 15732589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats.
    June HL; Cummings R; Eiler WJ; Foster KL; McKay PF; Seyoum R; Garcia M; McCane S; Grey C; Hawkins SE; Mason D
    Neuropsychopharmacology; 2004 Feb; 29(2):285-99. PubMed ID: 14603266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
    Michel ME; Bolger G; Weissman BA
    Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC; Kleppner SR; McDonough J; Azar MR; Patel R
    Int J Pharm; 2004 Sep; 283(1-2):35-44. PubMed ID: 15363499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats.
    Yong Z; Gao X; Ma W; Dong H; Gong Z; Su R
    Eur J Pharmacol; 2014 Sep; 738():153-7. PubMed ID: 24886878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.